Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects-Reference-Cited by-同舟云学术

Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects

Published:2018-08-09 Issue:10 Volume:84 Page:2422-2432
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Schneider Frank¹^ORCID,Erisson Lavi²,Beygi Hooman²,Bradbury Margaret³,Cohen-Barak Orit⁴,Grachev Igor D.⁵,Guzy Serge⁶,Loupe Pippa S.⁷,Levi Micha²,McDonald Mirna²,Savola Juha-Matti⁸,Papapetropoulos Spyros⁹,Tracewell William G.²,Velinova Maria¹⁰,Spiegelstein Ofer⁴

Affiliation:

1. Global Research and Development; Teva Pharmaceutical Industries; Berlin Germany

2. Global Research and Development; Teva Pharmaceutical Industries; West Chester PA USA

3. Formerly Global Research and Development Teva Pharmaceuticals; currently Prana Biotechnology; San Francisco CA USA

4. Global Research and Development; Teva Pharmaceutical Industries; Netanya Israel

5. Global Research and Development; Teva Pharmaceutical Industries; Malvern PA USA

6. Pop-Pharm Pharmacometrics Service; Albany CA USA

7. Global Research and Development; Teva Pharmaceutical Industries; Overland Park KS USA

8. Teva Pharmaceuticals International GmbH; Basel Switzerland

9. Massachusetts General Hospital; Boston MA USA

10. PRA Health Sciences; Early Development Services; Groningen the Netherlands

Funder

Teva Pharmaceutical Industries

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13702/fullpdf

Reference36 articles.

1. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015;GBD 2015 Disease and Injury Incidence and Prevalence Collaborators;Lancet,2016

2. Priorities in Parkinson's disease research;Meissner;Nat Rev Drug Discov,2011

3. Time of loss of employment in Parkinson's disease;Schrag;Mov Disord,2006

4. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease;Gallagher;CNS Drugs,2008

5. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine;Huebert;Drug Metab Dispos,1983

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DRD2 activation inhibits choroidal neovascularization in patients with Parkinson’s disease and age-related macular degeneration;Journal of Clinical Investigation;2024-07-16

2. Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson’s disease;Communications Biology;2024-05-30

3. Probing solution conformations of l-DOPA: Integration of experiment and simulation via vibrational optical activity;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2024-05

4. Enhancing the Properties of Natural Products and Other Drugs: Deuterium: A Novel Approach;Journal of Natural Remedies;2024-03-01

5. Chemoenzymatic β-specific methylene C(sp³)–H deuteration of carboxylic acids;Green Chemistry;2024